Investigational drug · Phase 2
ECC4703
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "ECC4703"
First trial start
2025
Dec 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ECC4703", any sponsor or status.
Conditions studied
As listed on its trial records.
- Adult Obesity
- Weight Management
- Metabolic Dysfunction-associated Steatohepatitis
Approved drugs for the same conditions: Obesity and weight management · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ECC4703" as an intervention, largest first.
EccogeneIndustry
NCT07288138 · 160 participants (planned) · Start Dec 15, 2025 · Primary completion Sep 15, 2027
Drug: Placebo; ECC4703 and 2 more · For: Metabolic Dysfunction-associated Steatohepatitis
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 70 sites in all
- MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialPivotal-lookingActive, not recruiting
EccogeneIndustry
NCT07505303 · 151 participants · Start Mar 23, 2026 · Primary completion Oct 15, 2026
Drug: ECC4703; Placebo and 1 more · For: Adult Obesity; Weight Management
Sites: Birmingham, Alabama; Anaheim, California; Los Alamitos, California · 15 sites in all
EccogeneIndustry
NCT05552274 · 75 participants · Start Aug 16, 2022 · Primary completion Oct 26, 2023
Drug: ECC4703; Placebo · For: Non-alcoholic Steatohepatitis (NASH)
Sites: Las Vegas, Nevada
EccogeneIndustry
NCT07334080 · 72 participants (planned) · Start Jan 7, 2026 · Primary completion Apr 2027
Drug: ECC4703 F0 formulation; ECC4703 F1 formulation and 2 more · For: Metabolic Dysfunction-Associated Steatohepatitis
Sites: Adelaide, Australia
EccogeneIndustry
NCT07726368 · 40 participants (planned) · Start Aug 7, 2026 · Primary completion Dec 2026
Drug: ECC4703; Sulfasalazine and 1 more · For: Non-alcoholic Fatty Liver Disease (NAFLD); Dyslipidaemia
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.